Precision NanoSystems NanoAssemblr Spark for screening of nanomedicine formulations

Tuesday, 01 March, 2022 | Supplied by: ATA Scientific Pty Ltd

Precision NanoSystems NanoAssemblr Spark for screening of nanomedicine formulations

Nanomedicines are believed to represent the next era in drug innovation, with improved performance, reduced side effects and new treatment strategies for otherwise ‘undruggable’ targets like personalised medicine. Consisting of active pharmaceutical ingredients (API) such as small molecules or nucleic acids, nanomedicines are packaged into nano-sized carriers like lipids and polymers that are designed to protect the cargo, enhance solubility and control distribution and targeted release.

Screening active ingredients, excipients and formulation conditions are important in the discovery and early development stages. Traditional methods used to develop nanomedicines can present several challenges. Ingredients can be costly or in limited supply, while the final product can lack consistency, have low throughput, be a slow and laborious process and be difficult to scale. The NanoAssemblr series from Precision NanoSystems is enabling drug innovators to overcome these and many other challenges by making purpose-designed manufacturing technology to support all stages of nanomedicine development.

The NanoAssemblr Spark offers the ability to formulate small-scale uniform particles using microlitre volumes quickly and reproducibly, with near complete sample recovery. Requiring little or no training, users can simply add starting materials into wells, push a button and pipette completed formulations in less than 10 s, allowing hundreds of formulations to be made in hours. Electronic control minimises batch-to-batch and user variability. Plus, formulations can be made on demand in a sterile hood for immediate cell culture application, making the Spark suitable for screening formulations that use scarce or expensive APIs or excipients.

Precision NanoSystems’ GenVoy-ILM T Cell Kit for mRNA accelerates T cell therapy from an idea to clinical applications.

For more information:

Phone: 02 9541 3500
Related Products

Waters Rheo-Impedance Spectroscopy (Rheo-IS) accessory

Waters has released an accessory for its TA Instruments Discovery Hybrid Rheometers (HR) that...

Omicron Laserage BrixXHUB Ultra high-power laser light engine

At the core of the device is the integration of up to six high-power BrixX lasers, offering a...

Waters Oasis WAX/GCB and GCB/WAX for PFAS Analysis cartridges

The dual-phase cartridges are designed to simplify and expedite the process of preparing complex...

  • All content Copyright © 2024 Westwick-Farrow Pty Ltd